More recently developed compounds, which are also able to bind FOXM1, promote its degradation, and inhibit breast cancer proliferation, show greater clinical promise [143], as comprehensively reviewed by Katzenellenbogen et al. [148]. The gene discussed is FOXM1; the disease is breast cancer.